COVID-19 vaccine sales boosted Pfizer earnings well past analyst expectations in the final quarter of 2021, but the drugmaker is setting a lower-than-expected bar for 2022.
Pfizer said Tuesday that it expects adjusted earnings in the new year to range from USD 6.35 to USD 6.55 per share on USD 98 billion to USD 102 billion in revenue.
Industry analysts were expecting earnings of USD 6.71 per share on USD 103.18 billion in revenue, according to FactSet.
Pfizer shares started sliding in early trading.
In the fourth quarter, Pfizer said its two-shot coronavirus vaccine, Comirnaty, brought in more than USD 12.5 billion in revenue, which helped the company's total top line double compared to the last quarter of 2020.
Pfizer books the vast majority of revenue from Comirnaty and splits profit, as well as the cost to make and distribute the vaccine, with development partner BioNTech.
Late in the fourth quarter, Pfizer also debuted Paxlovid, the first pill treatment to fight COVID-19. The new drug only generated USD 76 million in U.S. sales after receiving regulatory approval shortly before Christmas.
But analysts and Pfizer expect it to bring in about USD 22 billion in sales this year, according to FactSet.
Outside Comirnaty and Paxlovid, Pfizer products include several cancer treatments, other vaccines and internal medicine drugs like Eliquis, for preventing blood clots and strokes.
Overall, Pfizer reported adjusted earnings of USD 1.08 for the fourth quarter on USD 23.84 billion in revenue.
Analysts expected earnings of 87 cents per share on USD 24.16 billion in sales for the fourth quarter.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU